Else Nutrition applies for CSE listing

• The most recent release (May 7, 2026) states Else Nutrition has applied to list its common shares on the Canadian Securities Exchange (CSE).
• The Toronto Stock Exchange (TSX) granted a 30-day extension to the original delisting date of May 8, 2026.
• This extension is intended to ensure trading continuity while the CSE application is processed.
• The move follows a period of significant share price decline and regulatory developments regarding infant formula standards.

• Negative Sentiment: Transitioning from the TSX (a senior exchange) to the CSE (a junior exchange) is typically viewed negatively by institutional investors due to reduced liquidity, prestige, and visibility.
• Distress Signal: The need for a delisting extension confirms the company failed to meet TSX listing requirements, likely driven by the share price collapse from $0.25 to $0.03 (an 88% decline).
• Liquidity Risk: While the extension prevents an immediate trading halt, it does not resolve the underlying capital or compliance issues that led to the delisting risk.
• Contextual Failure: Despite positive regulatory news in late 2025 regarding FDA pathways and operational restructuring (Q3 2025 margin improvement), the market has punished the stock severely, culminating in this exchange downgrade.

• Overview: Else Nutrition Holdings Inc. develops plant-based, non-soy, non-dairy infant nutrition products.
• Flagship Project: Plant-based infant formula utilizing almonds, buckwheat, and tapioca.
• Development Status: Toddler/kids powder lines are commercialized (1 million cans sold milestone Jan 2026). Infant formula regulatory approval in the U.S. is pending FDA guidance finalization.
• Operations: Manufacturing via third-party partners; distribution shifting to direct-to-retail models in Canada and Israel.